Peripheral leukocyte anomaly detected with routine automated hematology analyzer sensitive to adipose triglyceride lipase deficiency manifesting neutral lipid storage disease with myopathy/triglyceride deposit cardiomyovasculopathy

Bruno, 2008, Lipid storage myopathies, Curr. Opin. Neurol., 21, 601, 10.1097/WCO.0b013e32830dd5a6 Laforêt, 2010, Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges, Neuromuscul. Disord., 20, 693, 10.1016/j.nmd.2010.06.018 Fischer, 2007, The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy, Nat. Genet., 39, 28, 10.1038/ng1951 Akiyama, 2007, Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy, Muscle Nerve, 36, 856, 10.1002/mus.20869 Kobayashi, 2008, The lack of the C-terminal domain of adipose triglyceride lipase causes neutral lipid storage disease through impaired interactions with lipid droplets, J. Clin. Endocrinol. Metab., 93, 2877, 10.1210/jc.2007-2247 Hirano, 2008, Triglyceride deposit cardiomyovasculopathy, N. Engl. J. Med., 359, 2396, 10.1056/NEJMc0805305 Hirano, 2009, A novel clinical entity: triglyceride deposit cardiomyovasculopathy, J. Atheroscler. Thromb., 16, 702, 10.5551/jat.1669 Hirano, 2014, Genetic mutations in adipose triglyceride lipase and myocardial up-regulation of peroxisome proliferated activated receptor-gamma in patients with triglyceride deposit cardiomyovasculopathy, Biochem. Biophys. Res. Commun., 443, 574, 10.1016/j.bbrc.2013.12.003 Reilich, 2011, The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene, J. Neurol., 258, 1987, 10.1007/s00415-011-6055-4 Tavian, 2012, Contribution of novel ATGL missense mutations to the clinical phenotype of NLSD-M: a strikingly low amount of lipase activity may preserve cardiac function, Hum. Mol. Genet., 21, 5318, 10.1093/hmg/dds388 K. Kaneko, H. Kuroda, R. Izumi, M. Tateyama, M. Kato, K. Sugimura, Y. Sakata, Y. Ikeda, K. Hirano, M. Aoki, A novel mutation in PNPLA2 causes neutral lipid storage disease with myopathy and triglyceride deposit cardiomyovasculopathy: a case report and literature review. Neuromuscul. Disord. (in press). http://dx.doi.org/10.1016/j.nmd.2014.04.001. Akman, 2010, Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene, Neuromuscul. Disord., 20, 397, 10.1016/j.nmd.2010.04.004 Perrin, 2013, PNPLA2 mutation: a paediatric case with early onset but indolent course, Neuromuscul. Disord., 23, 986, 10.1016/j.nmd.2013.08.008 Tauchi-Sato, 2002, The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition, J. Biol. Chem., 277, 44507, 10.1074/jbc.M207712200 Wang, 2011, ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases: diagnostic confirmation and management of presymptomatic individuals, Genet. Med., 13, 457, 10.1097/GIM.0b013e318211a7e1 Janssen, 2013, Symptomatic lipid storage in carriers for the PNPLA2 gene, Eur. J. Hum. Genet., 21, 807, 10.1038/ejhg.2012.256 Lefèvre, 2001, Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin–Dorfman syndrome, Am. J. Hum. Genet., 69, 1002, 10.1086/324121 Bruno, 2008, Clinical and genetic characterization of Chanarin–Dorfman syndrome, Biochem. Biophys. Res. Commun., 369, 1125, 10.1016/j.bbrc.2008.03.010 Bonnefont, 1999, Carnitine palmitoyltransferase deficiencies, Mol. Genet. Metab., 68, 424, 10.1006/mgme.1999.2938